Eli Lilly & Co. (LLY)

116.23
NYSE : Health Technology
Prev Close 116.01
Day Low/High 115.00 / 116.30
52 Wk Low/High 81.49 / 132.13
Avg Volume 16.03M
Exchange NYSE
Shares Outstanding 970.83M
Market Cap 112.63B
EPS 3.10
P/E Ratio 44.62
Div & Yield 2.58 (2.00%)
Midday Report: New Home Sales Highest Since 2008; U.S. Stocks Mixed

Midday Report: New Home Sales Highest Since 2008; U.S. Stocks Mixed

U.S. stocks retreat into the red as a number of positive and negative earnings reports keep trading choppy.

Cramer: Here's What's Really Behind This Hatred for Biotechs

This is the group that is the most dangerous politically.

Lilly's Charts Don't Prescribe an Outright Buy

Our quantitative service has upgraded the drug maker to a buy, but the technicals are not ready yet to join in.

LLY Investor Mtg.

2 Promising Biopharmas Reach Key Junctures

2 Promising Biopharmas Reach Key Junctures

FDA decision will impact Relypsa's buyout potential while Aritana won't stay this undervalued.

BofA/Merrill Healthcare Conf.

LLY Investor Mtg.

Midday Report: Consumer Sentiment Falls; U.S. Stocks See Choppy Trade

Midday Report: Consumer Sentiment Falls; U.S. Stocks See Choppy Trade

U.S. stocks lose earlier highs on Tuesday as the health care sector pulls the markets lower.

2 Small-Cap Stocks That Could Win Big

2 Small-Cap Stocks That Could Win Big

Investing in small-cap names take a lot of research and patience, but they can also be very rewarding.

Eli Lilly Revenue Beats, Facebook to Launch new Camera App

Eli Lilly Revenue Beats, Facebook to Launch new Camera App

Eli Lilly earnings came in short by 2 cents but revenue was slightly higher than estimates.

Jim Cramer: How Long Will the Bear Market in Biotech Continue?

Jim Cramer: How Long Will the Bear Market in Biotech Continue?

TheStreet's Jim Cramer isn't too fond of the pharmaceutical sector and he doesn't see that changing anytime soon.

Jim Cramer Is Bullish on Salesforce.com and Palo Alto Networks

Jim Cramer Is Bullish on Salesforce.com and Palo Alto Networks

TheStreet's Jim Cramer is on the floor of the NYSE talking MLB's Opening Day and answering social media questions.

Intermediate Trade: Eli Lilly

Intermediate Trade: Eli Lilly

Consider the LLY out-of-the-money, bearishly biased vertical put spread expiring in May.

Jim Cramer Says Eli Lilly’s Pipeline Is 'Challenged'

Jim Cramer Says Eli Lilly’s Pipeline Is 'Challenged'

TheStreet's Jim Cramer is concerned about what Eli Lilly has in its pipeline of new prospects.

Jim Cramer Likes Johnson & Johnson Over Eli Lilly in Pharma Sector

Jim Cramer Likes Johnson & Johnson Over Eli Lilly in Pharma Sector

TheStreet's Jim Cramer says Gilead (GILD) needs to make an acquisition to jump start its business.

That Was the Week That Was

That Was the Week That Was

Let's review.

CLOSED: Intermediate Trade: Eli Lilly

CLOSED: Intermediate Trade: Eli Lilly

Closing this trade now as gains are sweet and should be locked in.

Jim Cramer Says Avoid Airlines on Capacity Woes, Buy Eli Lilly

Jim Cramer Says Avoid Airlines on Capacity Woes, Buy Eli Lilly

TheStreet’s Jim Cramer commented on United Airlines and JetBlue on Tuesday from the floor of the New York Stock Exchange.

Jim Cramer Says Take a Long Term View on Healthcare Stocks

Jim Cramer Says Take a Long Term View on Healthcare Stocks

Jim Cramer says healthcare companies will be in the spotlight this week and investors should take a long term view of the sector if the stocks selloff.

Eli Lilly numbers increased at Leerink

What's Ahead Thursday: Why Investors Will Be Watching Eli Lilly

What's Ahead Thursday: Why Investors Will Be Watching Eli Lilly

In 'What's Ahead on Wall Street' for Thursday January 28, there are lots of earnings on tap but TheStreet highlights a few major ones.

Health Care Stocks Are Getting 'Uber-ed' by Ashton Kutcher

Two significant, but subtle forces may threaten the group in the next 12 months.

Cramer: There Are Not Enough Fundamental Buyers Out There

Lack of volume is causing the exaggerated market moves, right now.

Immunotherapy, Genomics Gains Make These ‘Lucky Years’ Says David Agus

Immunotherapy, Genomics Gains Make These ‘Lucky Years’ Says David Agus

Sky-high drug prices and rising insurance premiums are grabbing the daily headlines.

Cramer: Facts Get in the Way of Negativity

Aren't we being a bit too quick to write off 2016?

Midday Report: Fiat Chrysler Enjoys Best December in 90 Years

Midday Report: Fiat Chrysler Enjoys Best December in 90 Years

U.S. stocks returned to positive territory in Tuesday's trading session after Monday's steep selloff.

Jim Cramer's 2016 Prediction: Eli Lilly Will Hit $100 a Share

Jim Cramer's 2016 Prediction: Eli Lilly Will Hit $100 a Share

Jim Cramer made some predictions about the stock market in 2016 while answering viewers’ social media questions.

Jim Cramer Says General Mills Still a Stock to Hold for the Long Term

Jim Cramer Says General Mills Still a Stock to Hold for the Long Term

General Mills (GIS) is a still a stock to hold for the long term, even as the company missed on earnings due to a slump in cereal sales, says Cramer.

Jim Cramer on How to Play Defense in a Down Market Like Today

Jim Cramer on How to Play Defense in a Down Market Like Today

Jim Cramer, portfolio manager of TheStreet’s Action Alerts PLUS and host of CNBC’s ‘Mad Money,’ talked about how to play defense in a down market on Friday.

Eli Lilly upgraded at Deutsche